Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2021-06-17 Capital/Financing Update
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development expanderar sin portfölj genom nyinvestering i AnaCardio
Capital/Financing Update Classification · 1% confidence The document announces a specific corporate action: Karolinska Development AB acquiring a stake in AnaCardio AB and detailing the investment strategy related to financing clinical development. This is a material event announcement concerning corporate financing and investment activities. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). The content directly relates to capital structure changes and fundraising intentions, fitting best under 'Capital/Financing Update' (CAP). The length is moderate, and it is a direct announcement, not a placeholder for a larger report.
2021-06-17 Swedish
Karolinska Development expands its portfolio through new investment in AnaCardio
M&A Activity Classification · 1% confidence The document announces that Karolinska Development AB has acquired approximately 21% of the shares in AnaCardio AB, detailing the investment purpose and the target company's drug development focus. This is a specific corporate action related to investment and capital structure changes within the portfolio. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). It most closely aligns with an announcement regarding financing activities or capital structure changes related to portfolio companies, fitting the description of 'Capital/Financing Update' (CAP), as the investment is explicitly stated to cover costs prior to a planned major capital raising for clinical development. It is not a Director's Dealing (DIRS) or a Merger/Takeover (TAR).
2021-06-17 English
Karolinska Development increases book value of Dilafor that is indirectly owned via KDev Investments AB by SEK 450 million
Regulatory Filings Classification · 1% confidence The document is a press release announcing a change in the book value of a portfolio company (Dilafor) due to positive clinical trial results. It details the financial impact on the company's net result and per-share value. Since it is a specific corporate announcement regarding financial valuation and portfolio updates that does not fit into standard periodic reporting or other specific categories, it is classified as a Regulatory Filing (RNS) under the EU Market Abuse Regulation.
2021-06-17 English
Karolinska Development ökar det bokförda värdet av innehavet i portföljbolaget Dilafor som ägs indirekt via KDev Investments AB med SEK 450 miljoner
Regulatory Filings Classification · 1% confidence The document is a press release from Karolinska Development AB announcing a valuation increase of their portfolio company, Dilafor, following positive Phase 2b clinical trial results. This is a corporate announcement regarding financial impact and asset valuation, which does not fit into specific categories like earnings releases, dividends, or management changes. As it is a general regulatory announcement required by the EU Market Abuse Regulation, it falls under the RNS (Regulatory Filings) category.
2021-06-17 Swedish
Karolinska Developments portföljbolag Promimic undersöker förutsättningarna för en listning på Nasdaq First North Growth Market
Capital/Financing Update Classification · 1% confidence The document is an announcement from Karolinska Development AB regarding its portfolio company, Promimic, exploring a potential listing on Nasdaq First North Growth Market. This announcement concerns a potential future capital structure change or financing activity for the subsidiary, which is being communicated to the parent company's shareholders and the market. Since the core subject is the exploration of a stock listing (a form of capital/financing activity) by a portfolio company, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice. It is a specific corporate action update.
2021-06-11 Swedish
Karolinska Development’s portfolio company Promimic evaluates the possibility of a listing on Nasdaq First North Growth Market
Capital/Financing Update Classification · 1% confidence The document is a press release from Karolinska Development AB announcing that its portfolio company, Promimic, is evaluating a potential listing on Nasdaq First North Growth Market. This announcement concerns a potential future capital structure change or financing activity for the portfolio company, which is being communicated to the market by the parent investment company. Since the core subject is the evaluation of a listing (a form of capital raising/restructuring) and it is presented as a formal company announcement, it fits best under 'Capital/Financing Update' (CAP). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A). It is a specific corporate action update.
2021-06-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.